TargetCancer Foundation Successfully Engages And Empowers Rare Cancer Patients with Medrio

TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is remotely enrolling a total of 400 patients in the United States using electronic informed consent. Medrio’s eClinical solution provides significant benefits to TargetCancer Foundation including reduction of unnecessary delays, improved access to dispersed patients, privacy of review within the patient’s home environment, and increased patient and caregiver understanding.

Challenges

• Patient access without physical or geographical constraints
• Patient understanding of the molecular drivers of their rare cancer
• Lack of real-time visibility into the consent process